AbBC Therapies is pleased to announce that Claire Thuning-Roberson, PhD, Chief Executive Officer, will be presenting at the Immuno-Oncology 360° (IO360°) Summit 2026 in Boston.

Dr. Thuning-Roberson will discuss AbBC’s novel therapeutic platform leveraging Granzyme B fusion proteins as next-generation payloads designed to overcome key limitations of conventional antibody-drug conjugates (ADCs), including dose-limiting toxicity and drug resistance. The presentation will highlight how Granzyme B’s unique immune-derived mechanism of action enables potent, tumor-selective cell killing while avoiding bystander toxicity and resistance pathways commonly seen with chemotherapeutic payloads.

The IO360° Summit brings together leaders across immuno-oncology, cell therapy, and drug development to address emerging scientific, clinical, and translational challenges in the field.

Event: IO360° Summit 2026
Location: Boston, Massachusetts
Dates: February 10–12, 2026
Speaker: Claire Thuning-Roberson, PhD, CEO, AbBC Therapies

To read more, click here